A still from the "Rromantasy" commercial (Organon) The ad ends with a final nod to the genre, with the claim that Nexplanon is “over 99% effective, no matter the fantasy.” Organon pledges $30M ...

Potential Organon & Co. (NYSE:OGN) shareholders may wish to note that the CEO & Director, Kevin Ali, recently bought US$299k worth of stock, paying US$8.81 for each share. That's a very solid buy ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Organon saw significant volatility last month with a 30% decline in its share price, coinciding with the company's announcement of decreased earnings and a reduction in its dividend payout.

Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know. Organon beat analysts’ revenue expectations by 0.9% last ...

Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Organon (OGN).

JERSEY CITY, N.J., April 01, 2025--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...